著者

髙橋 良平 今井 浩一 菅井 沙知 吉田 栄充 中村 益美 浜野 晋一郎 岩﨑 文男

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.38, no.12, pp.741-750, 2012-12-10 (Released:2013-12-10)

参考文献数

28

被引用文献数

1

---

We evaluated ARCHITECT®・iCarbamazepine using chemiluminescent immunoassay (CLIA) with carbamazepine (CBZ) concentration in the serum of patients with epilepsy. The intra- and inter-assay coefficients of variation were 0.87-1.34% and 2.20-6.06%, respectively. Cross-reactivity of CBZ analogs by CLIA varied from 7.00-9.26% with carbamazepine-10,11-epoxide lower than that evaluated by fluorescence polarization immunoassay (FPIA), and 2.09-2.51% with 10-monohydroxycarbazepine higher than that evaluated by FPIA. Oxcarbazepine was not detected. In addition, we observed a correlation between the values obtained by CLIA method and the high performance liquid chromatography (HPLC) method (y = 1.07x - 0.09, r = 0.98), and FPIA method and HPLC method (y = 0.95x - 0.22, r = 0.97). Our results suggest that ARCHITECT®・iCarbamazepine measured the CBZ concentration in serum lower than that measured by FPIA. However we conclude that ARCHITECT®・iCarbamazepine can be used for routine monitoring of CBZ for the reason that ARCHITECT®・iCarbamazepine showed low cross-reactivity with CBZE by classification of CBZE/CBZ ratio.